IN2012DN04944A - - Google Patents

Download PDF

Info

Publication number
IN2012DN04944A
IN2012DN04944A IN4944DEN2012A IN2012DN04944A IN 2012DN04944 A IN2012DN04944 A IN 2012DN04944A IN 4944DEN2012 A IN4944DEN2012 A IN 4944DEN2012A IN 2012DN04944 A IN2012DN04944 A IN 2012DN04944A
Authority
IN
India
Prior art keywords
expression level
polq
breast cancer
patient
gene
Prior art date
Application number
Other languages
English (en)
Inventor
Christophe Cazaux
Jean-Sebastien Hoffmann
Jean-Christophe Bourdon
Da Silva Alice Machado
Henri Roche
Original Assignee
Centre Nat Rech Scient
Univ Toulouse 3 Paul Sabatier
Inst Claudius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Toulouse 3 Paul Sabatier, Inst Claudius filed Critical Centre Nat Rech Scient
Publication of IN2012DN04944A publication Critical patent/IN2012DN04944A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
IN4944DEN2012 2009-11-13 2010-11-12 IN2012DN04944A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306096A EP2322658A1 (fr) 2009-11-13 2009-11-13 Signature pour le diagnostic de l'agressivité et l'instabilité génétique du cancer du sein
PCT/EP2010/067401 WO2011058143A1 (fr) 2009-11-13 2010-11-12 Signature pour le diagnostic de l'agressivité du cancer du sein et de l'instabilité génétique du cancer du sein

Publications (1)

Publication Number Publication Date
IN2012DN04944A true IN2012DN04944A (fr) 2015-09-25

Family

ID=41647234

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4944DEN2012 IN2012DN04944A (fr) 2009-11-13 2010-11-12

Country Status (11)

Country Link
US (1) US8865408B2 (fr)
EP (2) EP2322658A1 (fr)
CN (1) CN102791879A (fr)
AU (1) AU2010317877A1 (fr)
BR (1) BR112012011247A2 (fr)
CA (1) CA2780479A1 (fr)
ES (1) ES2522992T3 (fr)
IL (1) IL219697A0 (fr)
IN (1) IN2012DN04944A (fr)
PT (1) PT2499258E (fr)
WO (1) WO2011058143A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2710142B1 (fr) * 2011-05-18 2017-04-26 Centre National de la Recherche Scientifique (CNRS) Signature pour le diagnostic de l'agressivité et l'instabilité génétique du cancer
EP2800821B1 (fr) * 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature pour le diagnostic de l'agressivité du cancer du poumon
CN102994627B (zh) * 2012-06-21 2015-04-15 宁波海尔施基因科技有限公司 一种肿瘤用药个体化指导的检测方法
US9157124B2 (en) 2012-09-18 2015-10-13 Institute For Cancer Research Systems and methods for diagnosing a predisposition to develop colon cancer
FR3019821A1 (fr) * 2014-04-14 2015-10-16 Centre Nat Rech Scient Nouveaux anticorps utiles pour le diagnostic et le pronostic du cancer
US10724100B2 (en) 2015-09-16 2020-07-28 Institute For Cancer Research Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
WO2017062754A1 (fr) * 2015-10-07 2017-04-13 New York University Compositions et procédés pour augmenter l'activité crispr par inhibition de polq
WO2017070198A1 (fr) * 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymérase q utilisée comme cible dans des cancers déficients en rh
CN106011262A (zh) * 2016-06-29 2016-10-12 北京泱深生物信息技术有限公司 子宫内膜癌诊治标志物及其应用
US12428663B2 (en) 2018-07-11 2025-09-30 The Johns Hopkins University Identification of DNA polymerase theta inactivation mechanism
AU2019418813A1 (en) 2018-12-31 2021-07-22 Tempus Ai, Inc. A method and process for predicting and analyzing patient cohort response, progression, and survival
US11875903B2 (en) 2018-12-31 2024-01-16 Tempus Labs, Inc. Method and process for predicting and analyzing patient cohort response, progression, and survival
US11599800B2 (en) * 2020-01-28 2023-03-07 Color Genomics, Inc. Systems and methods for enhanced user specific predictions using machine learning techniques
CN112725444A (zh) * 2020-12-30 2021-04-30 杭州联川基因诊断技术有限公司 一种检测pgr基因表达的引物、探针、试剂盒和检测方法
CN112646864A (zh) * 2020-12-30 2021-04-13 杭州联川基因诊断技术有限公司 一种检测esr1基因表达的引物、探针、试剂盒和检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
WO2007001684A2 (fr) 2005-05-19 2007-01-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition d'adn polymerase beta pour ameliorer l'efficacite d'agents anticancereux
AT504702A1 (de) * 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso

Also Published As

Publication number Publication date
PT2499258E (pt) 2014-11-04
WO2011058143A1 (fr) 2011-05-19
US8865408B2 (en) 2014-10-21
ES2522992T3 (es) 2014-11-20
IL219697A0 (en) 2012-07-31
EP2499258A1 (fr) 2012-09-19
CA2780479A1 (fr) 2011-05-19
EP2322658A1 (fr) 2011-05-18
EP2499258B1 (fr) 2014-08-06
CN102791879A (zh) 2012-11-21
AU2010317877A1 (en) 2012-06-07
BR112012011247A2 (pt) 2016-11-22
US20120021935A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
IN2012DN04944A (fr)
Chi et al. Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance.
UA110790C2 (uk) Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
WO2013153458A3 (fr) Méthode de pronostic et de traitement de métastases cancéreuses
WO2013182912A3 (fr) Méthode pour le diagnostic, le pronostic et le traitement d'une métastase du cancer du poumon
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
WO2014140933A8 (fr) Procédé de pronostic et de traitement de métastases cancéreuses
WO2012045905A3 (fr) Méthode de diagnostic, pronostic et traitement de la métastase du cancer du sein
WO2007140958A3 (fr) Procédé
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2011153545A3 (fr) Signature d'expression génique utilisée pour prédire une réponse à une chimiothérapie lors d'un cancer du sein
EP4083233A3 (fr) Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
WO2015052583A3 (fr) Méthode de pronostic et de traitement d'une métastase cancéreuse
WO2012174256A3 (fr) Profils de méthylation de l'adn dans le cancer
WO2008037700A3 (fr) Procédés pour pronostiquer un cancer du sein
ATE481504T1 (de) Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung
MX2011007795A (es) Polinucleotido que comprende secuencias de gliadinas de trigo y su uso para silenciamiento mediante rnai.
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
MX2013004747A (es) Marcadores de gen de sangre periferica para el diagnostico temprano de la enfermedad de parkinson.
Lee et al. A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2011134670A3 (fr) Procédé de diagnostic pour la prédiction de la réponse d'un patient à une chimio-virothérapie ou à une radio-virothérapie
WO2006133361A3 (fr) Utilisation du profilage de l'expression genique pour predire la survie d'un patient atteint de cancer
WO2012166700A3 (fr) Profilage moléculaire d'un microenvironnement de tumeur létale
WO2009091230A3 (fr) Marqueur protéique pour la surveillance, le diagnostic et le dépistage du cancer du sein, et méthode de surveillance, de diagnostic et de dépistage de cancer du sein faisant appel audit marqueur